Vertex Pharmaceutic (VRTX) 97.00 $VRTX
Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 6:13AM CDT
Although total revenues were just shy of expectations, Vertex's (VRTX) CF franchise sales improved sequentially.
BIIB: 289.93 (+0.90), VRTX: 97.00 (+0.79), INVA: 12.87 (+1.17), ANIP: 60.60 (+0.99)
Nivalis (NVLS): Can the Stock Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:46PM CDT
Nivalis Therapeutics (NVLS), which is expected to report second-quarter 2016 results on Aug 1, posted a negative surprise of 15.91% last quarter.
VRTX: 97.00 (+0.79), NVLS: 4.68 (-0.10), UTHR: 121.01 (+2.02), BMY: 74.81 (+0.15)
Vertex Reports Second Quarter 2016 Financial Results
BusinessWire - Wed Jul 27, 3:01PM CDT
---Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-
VRTX: 97.00 (+0.79)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 289.93 (+0.90), VRTX: 97.00 (+0.79), GILD: 79.47 (-1.77), ALXN: 128.60 (-1.80), AMGN: 172.03 (+0.75), ABBV: 66.23 (+1.51), CELG: 112.19 (+0.93)
5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:36AM CDT
How will drug stocks like AMGN, GSK, VRTX and others, scheduled to report on Jul 27, fare this earnings season?
BIIB: 289.93 (+0.90), JNJ: 125.23 (+0.77), VRTX: 97.00 (+0.79), MDCO: 39.11 (+0.22), AMGN: 172.03 (+0.75), GSK: 45.07 (-0.11), ANIK: 49.92 (+0.70)
Trek Therapeutics Acquires Two Antiviral Inhibitors From Vertex Pharmaceuticals
PR Newswire - Tue Jul 26, 8:30AM CDT
Trek Therapeutics, (TREKtx) a private, clinical stage public benefit corporation developing affordable and accessible treatment regimens for chronic hepatitis C virus (HCV) infection today announced that it acquired the worldwide development and commercialization rights to treat infectious disease with lomibuvir (VX-222), a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib (VX-497), an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties from Vertex Pharmaceuticals Incorporated.
VRTX: 97.00 (+0.79)
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 1.56% Gain
Comtex SmarTrend(R) - Mon Jul 25, 2:30PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $93.46 to a high of $95.36. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $94.29 on volume of 743,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 97.00 (+0.79)
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 1.56% Yesterday
Comtex SmarTrend(R) - Mon Jul 25, 2:28PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $93.46 to a high of $95.36. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $94.29 on volume of 743,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 97.00 (+0.79)
Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 6:54AM CDT
Will Orkambi and Kalydeco help Vertex (VRTX) surpass expectations in Q2?
VRTX: 97.00 (+0.79), BMRN: 99.42 (+1.22), ICPT: 173.03 (+6.13), AMGN: 172.03 (+0.75)
Vertex to Announce Second Quarter 2016 Financial Results on July 27
BusinessWire - Thu Jul 14, 7:30AM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
VRTX: 97.00 (+0.79)
SmarTrend Watching for Potential Rebound in Shares of Vertex Pharmaceuticals After 1.06% Loss
Comtex SmarTrend(R) - Wed Jul 13, 1:14PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.01 to a high of $90.41. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $88.65 on volume of 271,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 97.00 (+0.79)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 63.99 (+1.50), BIIB: 289.93 (+0.90), VRTX: 97.00 (+0.79), GILD: 79.47 (-1.77), UNH: 143.20 (+0.44), MRK: 58.66 (+0.23), ALXN: 128.60 (-1.80), XOM: 88.95 (-1.25), CVX: 102.48 (+0.69), REGN: 425.12 (+14.08), CELG: 112.19 (+0.93)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 3.12%
Comtex SmarTrend(R) - Wed Jul 06, 2:51PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.92 to a high of $89.90. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $88.46 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 97.00 (+0.79)
After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 06, 2:49PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.92 to a high of $89.90. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $88.46 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 97.00 (+0.79)
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics(TM) for Cystic Fibrosis
BusinessWire - Wed Jul 06, 7:14AM CDT
---Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with potential for up to additional $275 million in milestones plus royalty payments-
VRTX: 97.00 (+0.79)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 97.00 (+0.79), XON: 25.33 (+0.62), ARNA: 1.67 (-0.01), REGN: 425.12 (+14.08)
Claire's Place Foundation Receives Grant From Vertex Pharmaceuticals
GlobeNewswire - Wed Jun 22, 2:07AM CDT
Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis, is proud to announce that Vertex Pharmaceuticals Incorporated has awarded the foundation with a grant to support their Extended Hospital Stay Fund.
VRTX: 97.00 (+0.79)
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.28%
Comtex SmarTrend(R) - Thu Jun 16, 2:35PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.58 to a high of $90.42. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.52 on volume of 568,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 97.00 (+0.79)
Vertex Pharmaceuticals Falls 1.28% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 16, 2:34PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.58 to a high of $90.42. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.52 on volume of 568,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 97.00 (+0.79)
Vertex Announces Presentations of Data for KALYDECO(R) (ivacaftor) and ORKAMBI(R) (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference
BusinessWire - Fri Jun 10, 10:02AM CDT
---Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS-
VRTX: 97.00 (+0.79)
Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 6:13AM CDT
Although total revenues were just shy of expectations, Vertex's (VRTX) CF franchise sales improved sequentially.
BIIB: 289.93 (+0.90), VRTX: 97.00 (+0.79), INVA: 12.87 (+1.17), ANIP: 60.60 (+0.99)
Nivalis (NVLS): Can the Stock Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:46PM CDT
Nivalis Therapeutics (NVLS), which is expected to report second-quarter 2016 results on Aug 1, posted a negative surprise of 15.91% last quarter.
VRTX: 97.00 (+0.79), NVLS: 4.68 (-0.10), UTHR: 121.01 (+2.02), BMY: 74.81 (+0.15)
Vertex Reports Second Quarter 2016 Financial Results
BusinessWire - Wed Jul 27, 3:01PM CDT
---Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-
VRTX: 97.00 (+0.79)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 289.93 (+0.90), VRTX: 97.00 (+0.79), GILD: 79.47 (-1.77), ALXN: 128.60 (-1.80), AMGN: 172.03 (+0.75), ABBV: 66.23 (+1.51), CELG: 112.19 (+0.93)
5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:36AM CDT
How will drug stocks like AMGN, GSK, VRTX and others, scheduled to report on Jul 27, fare this earnings season?
BIIB: 289.93 (+0.90), JNJ: 125.23 (+0.77), VRTX: 97.00 (+0.79), MDCO: 39.11 (+0.22), AMGN: 172.03 (+0.75), GSK: 45.07 (-0.11), ANIK: 49.92 (+0.70)
Trek Therapeutics Acquires Two Antiviral Inhibitors From Vertex Pharmaceuticals
PR Newswire - Tue Jul 26, 8:30AM CDT
Trek Therapeutics, (TREKtx) a private, clinical stage public benefit corporation developing affordable and accessible treatment regimens for chronic hepatitis C virus (HCV) infection today announced that it acquired the worldwide development and commercialization rights to treat infectious disease with lomibuvir (VX-222), a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib (VX-497), an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties from Vertex Pharmaceuticals Incorporated.
VRTX: 97.00 (+0.79)
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 1.56% Gain
Comtex SmarTrend(R) - Mon Jul 25, 2:30PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $93.46 to a high of $95.36. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $94.29 on volume of 743,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 97.00 (+0.79)
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 1.56% Yesterday
Comtex SmarTrend(R) - Mon Jul 25, 2:28PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $93.46 to a high of $95.36. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $94.29 on volume of 743,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 97.00 (+0.79)
Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 6:54AM CDT
Will Orkambi and Kalydeco help Vertex (VRTX) surpass expectations in Q2?
VRTX: 97.00 (+0.79), BMRN: 99.42 (+1.22), ICPT: 173.03 (+6.13), AMGN: 172.03 (+0.75)
Vertex to Announce Second Quarter 2016 Financial Results on July 27
BusinessWire - Thu Jul 14, 7:30AM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
VRTX: 97.00 (+0.79)
SmarTrend Watching for Potential Rebound in Shares of Vertex Pharmaceuticals After 1.06% Loss
Comtex SmarTrend(R) - Wed Jul 13, 1:14PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.01 to a high of $90.41. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $88.65 on volume of 271,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 97.00 (+0.79)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 63.99 (+1.50), BIIB: 289.93 (+0.90), VRTX: 97.00 (+0.79), GILD: 79.47 (-1.77), UNH: 143.20 (+0.44), MRK: 58.66 (+0.23), ALXN: 128.60 (-1.80), XOM: 88.95 (-1.25), CVX: 102.48 (+0.69), REGN: 425.12 (+14.08), CELG: 112.19 (+0.93)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 3.12%
Comtex SmarTrend(R) - Wed Jul 06, 2:51PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.92 to a high of $89.90. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $88.46 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 97.00 (+0.79)
After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 06, 2:49PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.92 to a high of $89.90. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $88.46 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 97.00 (+0.79)
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics(TM) for Cystic Fibrosis
BusinessWire - Wed Jul 06, 7:14AM CDT
---Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with potential for up to additional $275 million in milestones plus royalty payments-
VRTX: 97.00 (+0.79)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 97.00 (+0.79), XON: 25.33 (+0.62), ARNA: 1.67 (-0.01), REGN: 425.12 (+14.08)
Claire's Place Foundation Receives Grant From Vertex Pharmaceuticals
GlobeNewswire - Wed Jun 22, 2:07AM CDT
Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis, is proud to announce that Vertex Pharmaceuticals Incorporated has awarded the foundation with a grant to support their Extended Hospital Stay Fund.
VRTX: 97.00 (+0.79)
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.28%
Comtex SmarTrend(R) - Thu Jun 16, 2:35PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.58 to a high of $90.42. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.52 on volume of 568,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 97.00 (+0.79)
Vertex Pharmaceuticals Falls 1.28% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 16, 2:34PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.58 to a high of $90.42. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.52 on volume of 568,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 97.00 (+0.79)
Vertex Announces Presentations of Data for KALYDECO(R) (ivacaftor) and ORKAMBI(R) (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference
BusinessWire - Fri Jun 10, 10:02AM CDT
---Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS-
VRTX: 97.00 (+0.79)
